Elagolix 150 mg每日一次与含炔雌醇/诺孕酯或炔诺酮口服避孕药合用的药动学与药效学特征
两项I期研究在健康绝经前女性中评估Elagolix 150 mg每日一次与含炔雌醇0.035 mg/诺孕酯0.18/0.215/0.25 mg的复方口服避孕药或仅含孕激素的炔诺酮0.35 mg避孕药合用的潜在药物相互作用。结果显示复方避孕药中炔雌醇暴露增加30%,诺孕酯代谢物降低约15%,炔诺酮暴露相当,FSH、LH和雌二醇暴露相似或更低,孕酮排卵浓度百分比相当,避孕药药效学特征得以维持。
要点
- Elagolix 150 mg每日一次与复方口服避孕药合用使炔雌醇暴露增加30%,诺孕酯代谢物降低约15%。
- 与炔诺酮0.35 mg合用对炔诺酮药动学暴露无显著影响。
- 合用期间FSH、LH和雌二醇暴露相似或更低,排卵期孕酮浓度百分比相当,避孕药药效学维持。
核心结论
- Elagolix 150 mg每日一次与含炔雌醇/诺孕酯的复方口服避孕药或炔诺酮合用仅引起口服避孕药组分的轻微药动学变化。
- 合用期间观察到FSH、LH和雌二醇暴露相似或更低,排卵期孕酮浓度也相当。
- 与Elagolix合用时口服避孕药的药效学特征得以维持。
研究设计与样本
- 两项I期研究采用两阶段序贯设计,在健康绝经前女性中开展。
- 第一阶段单用口服避孕药,第二阶段口服避孕药与Elagolix 150 mg每日一次合用。
- 研究1评估含炔雌醇0.035 mg和诺孕酯0.18/0.215/0.25 mg的复方口服避孕药,研究2评估仅含孕激素的炔诺酮0.35 mg避孕药。
主要发现
- 研究1中,与Elagolix合用时炔雌醇药动学暴露增加30%,诺孕酯代谢物降低约15%。
- 研究1中,FSH、LH和雌二醇的平均激素暴露分别降低31%、38%和16%。
- 研究1中,连续孕酮浓度高于5 nmol/L的女性百分比在两个阶段相似。
- 研究2中,炔诺酮药动学暴露在两个阶段相当。
- 研究2中,LH和FSH激素暴露相似,雌二醇平均暴露降低32%,连续排卵期孕酮浓度受试者百分比相似。
临床怎么用
- 临床合用时无需因药动学轻微变化而调整Elagolix 150 mg每日一次或口服避孕药的剂量。
- 合用时口服避孕药的药效学避孕效果得以维持,但FSH、LH和雌二醇暴露可能降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two pharmacokinetic/pharmacodynamic studies were conducted to evaluate the potential drug-drug interaction between elagolix, an oral gonadotropin-releasing hormone receptor antagonist, and an oral contraceptive (ethinylestradiol [EE] 0.035 mg and norgestimate 0.18/0.215/0.25 mg) or progestin-only contraceptive (norethindrone 0.35 mg) in healthy premenopausal women. METHODS: These phase I studies used a two-period, sequential design, where period 1 included treatment with oral contraceptives, followed by period 2 with contraceptives coadministered with elagolix 150 mg once daily. RESULTS: In study 1, pharmacokinetic exposures for EE in period 2 increased by 30% and the norgestimate metabolites decreased by approximately 15% when coadministered with elagolix. Mean hormone exposure appeared lower for follicle-stimulating hormone (FSH; 31%), luteinizing hormone (LH; 38%), and estradiol (E2; 16%). The percentage of women with consecutive progesterone (P) concentrations above 5 nmol/L was similar in both periods. Norethindrone pharmacokinetic exposures were comparable in both periods. The hormone exposure for LH and FSH was similar, and mean E2 exposure was 32% lower in period 2. The percentage of subjects with consecutive ovulatory P concentrations was also similar in both periods (study 2). Safety and tolerability profiles were unremarkable in both studies. CONCLUSIONS: Coadministration of elagolix 150 mg once daily with oral contraceptives containing EE and norgestimate, or norethindrone, resulted in small pharmacokinetic changes in the oral contraceptive components. Similar or lower FSH, LH, and E2 exposures were observed during coadministration, with ovulatory P concentrations also comparable in both periods. The pharmacodynamic profiles of the oral contraceptives were maintained when coadministered with elagolix.
引用
- Feldman RA, Chiu YL, Klein CE, et al. Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women. Clin Pharmacokinet. 2021. PMID: 33748934. doi:10.1007/s40262-021-00989-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。